Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 87,274
  • Shares Outstanding, K 70,382
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,340 K
  • EBIT $ -33 M
  • EBITDA $ -23 M
  • 60-Month Beta 2.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.22

Options Overview Details

View History
  • Implied Volatility 136.26% ( -60.33%)
  • Historical Volatility 59.18%
  • IV Percentile 43%
  • IV Rank 13.23%
  • IV High 737.40% on 01/03/24
  • IV Low 44.61% on 05/15/24
  • Put/Call Vol Ratio 0.75
  • Today's Volume 886
  • Volume Avg (30-Day) 1,492
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 106,953
  • Open Int (30-Day) 99,524

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +399,700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0700 +14.02%
on 10/24/24
1.3900 -12.23%
on 11/13/24
+0.0300 (+2.52%)
since 10/21/24
3-Month
1.0700 +14.02%
on 10/24/24
1.3900 -12.23%
on 11/13/24
-0.0900 (-6.87%)
since 08/21/24
52-Week
0.4986 +144.69%
on 01/26/24
1.7200 -29.07%
on 04/23/24
+0.2500 (+25.77%)
since 11/21/23

Most Recent Stories

More News
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SLS : 1.2200 (-1.61%)
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

SLS : 1.2200 (-1.61%)
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SLS : 1.2200 (-1.61%)
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

SLS : 1.2200 (-1.61%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

ATNM : 1.4700 (+5.76%)
BPTH : 0.7990 (+1.43%)
LGVN : 1.8700 (+1.08%)
SLS : 1.2200 (-1.61%)
BMY : 58.23 (+0.60%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

ATNM : 1.4700 (+5.76%)
BPTH : 0.7990 (+1.43%)
LGVN : 1.8700 (+1.08%)
SLS : 1.2200 (-1.61%)
BMY : 58.23 (+0.60%)
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)

/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced...

SLS : 1.2200 (-1.61%)
SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines

- Results Demonstrate Significant Anti-Tumor Effects on All Selected Cell Lines - - In Three of the Four Cell Lines, GFH009 Inhibited Cancer Growth by 90...

SLS : 1.2200 (-1.61%)
SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009

The Company Continues to Evaluate Optimal Dosing for Patients with Acute Myeloid Leukemia and Lymphoma in Preparation for Phase 2...

SLS : 1.2200 (-1.61%)
SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial

- No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose Levels Studied To-Date - - Early Indications of...

SLS : 1.2200 (-1.61%)

Business Summary

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present...

See More

Key Turning Points

3rd Resistance Point 1.3583
2nd Resistance Point 1.3067
1st Resistance Point 1.2633
Last Price 1.2200
1st Support Level 1.1683
2nd Support Level 1.1167
3rd Support Level 1.0733

See More

52-Week High 1.7200
Fibonacci 61.8% 1.2534
Last Price 1.2200
Fibonacci 50% 1.1093
Fibonacci 38.2% 0.9652
52-Week Low 0.4986

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar